Gilead Sciencesvs.Neurocrine Biosciences
GILD vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 11× larger than Neurocrine Biosciences by market cap; year to date, Gilead Sciences leads (+19.6% vs +7.9%).
Side by side
| GILD | NBIX | |
|---|---|---|
| Market cap | $170B | $15.5B |
| Price | $148.77 | $153.37 |
| Today | +1.4% | +0.2% |
| Return YTD | +19.6% | +7.9% |
| Return 1Y | +27.9% | +13.0% |
| P/E | — | 22.0 |
| P/S | 5.6 | 4.6 |
| P/B | 14.4 | 4.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →More GILD & NBIX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where GILD and NBIX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →